Dicerna Pharma (DRNA) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Jefferies Reiterates Buy on Dicerna Pharma (DRNA) Following 4Q - PT to $19
March 11, 2016 9:38 AM ESTJefferies maintained a Buy rating on Dicerna Pharmaceuticals (NASDAQ: DRNA), and cut the price target to $19.00 (from $25.00), following the company's 4Q. DRNA reported a Narrower 4Q15 net loss of $15.7M, compared to Jefferies' net loss estimate of $18.1M.
Analyst Eun Yang... More
